TLDR
- Citi downgraded Moderna to Sell from Hold, raising its price target to $80 from $60.
- Moderna stock fell 5.7% to $191.96 in premarket trading Wednesday.
- Shares had rallied roughly 222% since mid-August on cancer vaccine trial news.
- Citi says reaching $200 per share would require about $13 billion in annual oncology revenue, nearly 7x its current model.
- Wall Street holds a Hold consensus overall, with an average price target of $110.44, implying about 45% downside.
Citi has turned bearish on Moderna. Analyst Geoff Meacham cut his rating on the stock to Sell from Hold on Wednesday.
The move comes after a stunning run for Moderna shares. The stock has climbed roughly 222% since mid-August.
That surge followed a clinical update on intismeran autogene, the cancer vaccine Moderna is developing with Merck. The drug hit its main goals in a Phase 3 melanoma study.
Investors cheered the news. But Citi thinks the market has gotten ahead of itself.
Meacham raised his price target to $80 from $60. That’s still about 61% below Moderna’s last closing price of $203.46.
Moderna stock dropped 5.7% to $191.96 in premarket trading Wednesday following the downgrade.
What’s Driving the Downgrade
Citi’s core argument is about valuation. Moderna’s market cap has climbed to roughly $80 billion, putting it near Regeneron.
But the financials don’t match up. Consensus estimates call for Moderna to generate about $5.8 billion in revenue and $1.1 billion in net income by 2030.
Regeneron, by comparison, is expected to post $22.7 billion in revenue and $8 billion in net income over the same period. Citi says that gap suggests investors are pricing in a lot of pipeline success that hasn’t happened yet.
Even if Citi gave intismeran a 100% chance of success across its major cancer programs, the firm says that would only support around $100 per share. Getting to $200 would require about $13 billion in annual oncology revenue, nearly seven times what Citi currently models.
Meacham called that sales assumption unrealistic.
The Data Still to Come
Citi isn’t disputing the positive headline results from the INTerpath-001 trial. The study met its recurrence-free survival and distant metastasis-free survival goals.
But the actual numbers haven’t been released yet. Key details like hazard ratio, safety, and manufacturing feasibility remain unknown.
Meacham said a hazard ratio around 0.72 would be clinically credible. Anything at 0.65 or lower would count as a clear win.
For context, an earlier Phase 2 study showed a five-year hazard ratio of 0.51. That sets a high bar for the upcoming Phase 3 data.
Melanoma also responds particularly well to immunotherapy compared with other cancers. Meacham cautioned that success there doesn’t guarantee the drug will work in kidney, lung, or bladder cancers, each of which has different biology and competition.
The next major data readout is expected at the European Society for Medical Oncology meeting in late October.
Wall Street remains split on Moderna overall. Of 20 analysts covering the stock, six rate it a Buy, most rate it a Hold, and only a couple carry a Sell rating.
The average price target across the Street sits at $110.44. That implies roughly 45% downside from current levels.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
